GO:0044258 intestinal lipid catabolic process: Lipid Digestion Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0044258 intestinal lipid catabolic process describes the breakdown of dietary lipids into fatty acids and monoglycerides in the small intestine, primarily through pancreatic lipases.
• This process is essential for the absorption of dietary fats and fat-soluble nutrients, and its dysregulation contributes to hypertriglyceridemia and related metabolic disorders.
• Key enzymes include pancreatic triacylglycerol lipase (PNLIP), colipase (CLPS), and carboxyl ester lipase (CEL), which act in the intestinal lumen.
• The process is regulated by hormonal signals such as glucagon and thyroid hormones, which modulate lipase secretion and activity.
• Experimental models for studying intestinal lipid catabolism include knockout mice, point-mutation knock-in models, and overexpression systems, often combined with lipidomics and transcriptomics.
• CRISPR-based screening and bioinformatics can identify novel regulators of this pathway, offering targets for metabolic disease intervention.
Description
The intestinal lipid catabolic process (GO:0044258) is a vital biological process that enables the breakdown of dietary lipids into absorbable fatty acids and monoglycerides within the small intestine. This process is primarily mediated by pancreatic lipases released into the intestinal lumen, where they hydrolyze triacylglycerols and other lipids. Efficient lipid catabolism is crucial for energy homeostasis and the uptake of essential fatty acids and fat-soluble vitamins. Dysregulation of this pathway is linked to metabolic disorders such as hypertriglyceridemia and obesity, making it a key area of biomedical research. Understanding the molecular players and regulatory mechanisms of intestinal lipid catabolism can inform therapeutic strategies for dyslipidemias and related diseases. This article provides a comprehensive overview of the genes, functions, and research methods associated with GO:0044258, based on authoritative QuickGO data and published literature.
intestinal lipid catabolic process At A Glance
| GO ID | GO:0044258 |
|---|---|
| GO term | intestinal lipid catabolic process |
| Ontology | biological_process |
| Synonym | intestinal lipid breakdown, intestinal lipid catabolism, intestinal lipid degradation |
| Major function | Breakdown of lipids into fatty acids and monoglycerides in the small intestine |
| Location | Small intestine lumen and brush border |
| Key enzymes | Pancreatic lipases (e.g., PNLIP, CLPS, CEL) |
| Regulatory hormones | Glucagon, thyroid hormones, catecholamines |
What Is GO:0044258?
According to the Gene Ontology, intestinal lipid catabolic process (GO:0044258) is defined as the chemical reactions and pathways resulting in the breakdown of lipids into fatty acids and monoglycerides in the small intestine. This process is carried out by lipases that are released by the pancreas. It encompasses the hydrolysis of dietary triacylglycerols, phospholipids, and cholesteryl esters, facilitating the absorption of lipid-derived nutrients.
Why Is intestinal lipid catabolic process Important in Cell Biology?
Intestinal lipid catabolism is essential for the efficient absorption of dietary fats, which serve as a major energy source and provide essential fatty acids for membrane synthesis and signaling. Impairments in this process can lead to steatorrhea, fat-soluble vitamin deficiencies, and metabolic disorders such as hypertriglyceridemia and obesity. Moreover, the intestine is a key site for the regulation of systemic lipid homeostasis, and understanding this process has implications for developing therapies for dyslipidemias and cardiovascular diseases.
• Enables absorption of dietary fats and fat-soluble vitamins.
• Provides energy and essential fatty acids for systemic metabolism.
• Dysregulation contributes to hypertriglyceridemia and cardiovascular risk.
• Target for anti-obesity and lipid-lowering interventions.
• Influences intestinal lymphatic transport of drugs and nutrients.
• Modulated by gut microbiota and dietary components.
• Regulated by hormones such as glucagon and thyroid hormones.
• Key to understanding postprandial lipemia and metabolic syndrome.
• Relevant to drug delivery via oleosomes and lipid-based formulations.
• Provides insights into evolutionarily conserved lipid handling mechanisms.
What Happens During intestinal lipid catabolic process?
Emulsification of dietary lipids
In simple terms: Fats are broken into tiny droplets so enzymes can access them.
Dietary lipids are emulsified by bile salts in the small intestine, forming mixed micelles that increase the surface area for lipase action. This step is critical for the efficient hydrolysis of triacylglycerols by pancreatic lipases.
Pancreatic lipase secretion and activation
In simple terms: The pancreas releases enzymes that digest fats.
The pancreas secretes lipases such as pancreatic triacylglycerol lipase (PNLIP) and colipase (CLPS) into the duodenum in response to hormonal signals like cholecystokinin and secretin. Colipase anchors lipase to the lipid-water interface, enhancing its activity.
Hydrolysis of triacylglycerols
In simple terms: Enzymes cut fats into absorbable pieces.
Pancreatic lipase hydrolyzes triacylglycerols into 2-monoacylglycerols and free fatty acids. Carboxyl ester lipase (CEL) also contributes to the hydrolysis of cholesteryl esters and retinyl esters.
Absorption of fatty acids and monoglycerides
In simple terms: The breakdown products are taken up by intestinal cells.
Free fatty acids and monoglycerides are absorbed by enterocytes via passive diffusion and transporter-mediated uptake, then re-esterified into triacylglycerols for packaging into chylomicrons.
Regulation by hormones and nutrients
In simple terms: Hormones and diet control how fast fats are digested.
Glucagon and thyroid hormones modulate lipase secretion and activity. Dietary sphingolipids and gut microbial metabolites can also influence intestinal lipid catabolism.
Key Genes Involved in GO:0044258 intestinal lipid catabolic process
The following genes and proteins are central to the intestinal lipid catabolic process, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PNLIP | Pancreatic triacylglycerol lipase; hydrolyzes triacylglycerols | Target for lipid-lowering therapies; KO models show fat malabsorption |
| CLPS | Colipase; anchors lipase to lipid droplets | Essential for lipase activity; mutations linked to fat malabsorption |
| CEL | Carboxyl ester lipase; hydrolyzes cholesteryl esters | Broad substrate specificity; role in cholesterol absorption |
| PLA2G1B | Pancreatic phospholipase A2; hydrolyzes phospholipids | Involved in phospholipid digestion; KO mice show altered lipid metabolism |
| LIPF | Gastric lipase; initiates lipid digestion in stomach | Contributes to pre-duodenal lipolysis; species-specific |
| FABP1 | Liver-type fatty acid-binding protein; transports fatty acids | Facilitates intracellular fatty acid trafficking |
| FATP4 | Fatty acid transport protein 4; uptake of long-chain fatty acids | Enterocyte fatty acid uptake; KO mice are lean |
| CD36 | Fatty acid translocase; facilitates fatty acid uptake | Important for chylomicron formation |
| MOGAT2 | Monoacylglycerol acyltransferase 2; re-esterifies monoglycerides | Key for triacylglycerol resynthesis in enterocytes |
| DGAT1 | Diacylglycerol acyltransferase 1; final step of triacylglycerol synthesis | Target for obesity; KO mice resist diet-induced obesity |
| APOB | Apolipoprotein B; structural component of chylomicrons | Required for chylomicron assembly and lipid transport |
| MTTP | Microsomal triglyceride transfer protein; loads lipids onto APOB | Mutations cause abetalipoproteinemia |
| ANGPTL4 | Angiopoietin-like 4; inhibits lipoprotein lipase | Regulates plasma triglyceride clearance |
| APOC3 | Apolipoprotein C-III; inhibits lipoprotein lipase | Target for hypertriglyceridemia therapies |
| LPL | Lipoprotein lipase; hydrolyzes plasma triacylglycerols | Peripheral lipid catabolism; not intestinal but related |
| NR1H2 | Liver X receptor beta; regulates lipid metabolism | Modulates intestinal lipid absorption |
| PPARA | Peroxisome proliferator-activated receptor alpha | Regulates fatty acid oxidation and lipid transport |
| SREBF1 | Sterol regulatory element-binding transcription factor 1 | Controls lipogenic gene expression |
How Is intestinal lipid catabolic process Regulated?
The intestinal lipid catabolic process is regulated at multiple levels. Hormones such as glucagon and thyroid hormones modulate pancreatic lipase secretion and activity. Dietary components, including sphingolipids, can lower plasma cholesterol and triacylglycerol levels by affecting intestinal lipid handling. Gut microbial fatty acid isomerization can influence intraepithelial T cells and lipid metabolism. Additionally, transcription factors like PPARA and SREBF1 regulate genes involved in lipid uptake and oxidation.
intestinal lipid catabolic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| APOC3 | Hypertriglyceridemia | Knockout mouse; overexpression in hepatocytes |
| ANGPTL4 | Dyslipidemia | Knock-in point mutation; KO mouse |
| MTTP | Abetalipoproteinemia | Knockout intestinal cell line; patient-derived iPSCs |
| PNLIP | Chronic pancreatitis | Point mutation knock-in mouse; KO zebrafish |
| DGAT1 | Obesity | Knockout mouse; overexpression in adipose tissue |
Hypertriglyceridemia and cardiovascular disease
Impaired intestinal lipid catabolism can lead to elevated plasma triglycerides, a risk factor for cardiovascular disease. Mutations in genes such as APOC3 and ANGPTL4 affect triglyceride clearance and are linked to hypertriglyceridemia.
Obesity and metabolic syndrome
Dysregulation of intestinal lipid absorption contributes to obesity and metabolic syndrome. Targeting enzymes like DGAT1 or MOGAT2 can reduce fat absorption and ameliorate obesity in preclinical models.
Fat malabsorption and steatorrhea
Defects in pancreatic lipase or colipase can cause fat malabsorption, leading to steatorrhea and fat-soluble vitamin deficiencies. Genetic mutations in PNLIP or CLPS are associated with chronic pancreatitis and malabsorption.
Abetalipoproteinemia
Mutations in MTTP impair chylomicron assembly, causing abetalipoproteinemia, a rare disorder characterized by fat malabsorption and neurological symptoms.
From intestinal lipid catabolic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X regulate intestinal lipid catabolism? | Knockout mouse or CRISPR KO cell line |
| Does a specific point mutation in gene Y affect lipase activity? | Point mutation knock-in mouse or cell line |
| Can overexpression of gene Z enhance lipid breakdown? | Transgenic overexpression mouse or lentiviral overexpression |
| What is the tissue-specific role of gene A in enterocytes? | Conditional knockout (Cre-lox) mouse |
| How does a tagged version of protein B localize in enterocytes? | Tagged knock-in (e.g., GFP) mouse or cell line |
| Which genes are essential for intestinal lipid absorption? | CRISPR library screening in intestinal organoids |
How to Study the intestinal lipid catabolic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Lipidomics (LC-MS) | Lipid species and abundance | Profiling lipid changes in KO vs WT |
| RNA-seq | Gene expression changes | Identifying regulators of lipid catabolism |
| Proteomics | Protein abundance and modifications | Detecting lipases in intestinal lumen |
| Enzyme activity assay | Lipase catalytic activity | Measuring PNLIP or CEL activity |
| Fluorescent lipid tracers | Lipid uptake and trafficking | Visualizing absorption in enterocytes |
| CRISPR screening | Gene essentiality for lipid catabolism | Identifying novel regulators |
| Intestinal organoids | Ex vivo lipid processing | Modeling human intestinal lipid absorption |
| Chylomicron secretion assay | Lipoprotein assembly and secretion | Assessing fat absorption |
Lipidomics and mass spectrometry
Lipidomics allows comprehensive profiling of lipid species before and after intestinal lipid catabolism, quantifying fatty acids, monoglycerides, and triacylglycerols. Mass spectrometry-based approaches are essential for measuring lipase activity and substrate specificity.
Transcriptomics and RNA-seq
RNA sequencing of intestinal tissues or organoids can identify genes differentially expressed during lipid catabolism, revealing regulatory networks. This method is useful for comparing wild-type and knockout models.
Proteomics and enzyme activity assays
Proteomic profiling of intestinal contents or brush border membranes can detect lipases and cofactors. Enzyme activity assays using synthetic substrates measure lipase activity directly.
Imaging and tracer studies
Fluorescent or radioactive lipid tracers can visualize lipid uptake and processing in live cells or whole animals. Intravital microscopy of intestinal villi allows real-time observation of lipid absorption.
How CRISPR Can Be Used to Study GO:0044258 intestinal lipid catabolic process
Knockout
CRISPR knockout of genes such as PNLIP, CLPS, or CEL in intestinal cell lines or mouse models can elucidate their roles in lipid catabolism. Knockout organoids can be used to study lipid absorption defects.
Point Mutation
Introducing disease-associated point mutations (e.g., in PNLIP) via CRISPR knock-in allows functional analysis of variants linked to pancreatitis or malabsorption. This approach helps distinguish loss-of-function from gain-of-function effects.
Knock-in
Tagged knock-in of lipid metabolism genes (e.g., GFP-tagged FABP1) enables live-cell imaging and protein localization studies in enterocytes. Knock-in of reporter genes can also monitor promoter activity.
Overexpression
CRISPR activation (CRISPRa) or transgenic overexpression of genes like DGAT1 or MOGAT2 can enhance lipid catabolism and storage, providing models for studying obesity and lipid handling.
How EDITGENE Supports intestinal lipid catabolic process Research
Researchers studying intestinal lipid catabolic process-related genes often need to determine whether a candidate gene is causally involved in lipid breakdown, absorption, or metabolic disease. EDITGENE provides comprehensive CRISPR-based services to generate precisely engineered cell and animal models, enabling functional validation and mechanistic studies.
Contact EDITGENE today to design your custom CRISPR model for intestinal lipid catabolic process research.
Frequently Asked Questions About intestinal lipid catabolic process
What is intestinal lipid catabolic process?
It is the biological process (GO:0044258) where dietary lipids are broken down into fatty acids and monoglycerides in the small intestine by pancreatic lipases.
What genes are involved in intestinal lipid catabolic process?
Key genes include PNLIP, CLPS, CEL, FABP1, FATP4, CD36, MOGAT2, DGAT1, APOB, and MTTP.
Where does intestinal lipid catabolism occur?
It occurs primarily in the lumen of the small intestine, where pancreatic lipases are released.
What enzymes break down lipids in the small intestine?
Pancreatic triacylglycerol lipase (PNLIP), colipase (CLPS), carboxyl ester lipase (CEL), and phospholipase A2 (PLA2G1B) are major enzymes.
How is intestinal lipid catabolism regulated?
It is regulated by hormones such as glucagon and thyroid hormones, as well as dietary factors and gut microbiota.
What diseases are associated with defects in intestinal lipid catabolism?
Hypertriglyceridemia, obesity, fat malabsorption, steatorrhea, and abetalipoproteinemia.
How can I study intestinal lipid catabolic process in the lab?
Using lipidomics, RNA-seq, proteomics, enzyme assays, and CRISPR knockout models in intestinal cells or organoids.
What CRISPR models are available for studying lipid catabolism?
Knockout, point mutation knock-in, tagged knock-in, and overexpression models in cell lines and mice.
What is the role of pancreatic lipase in intestinal lipid catabolism?
Pancreatic lipase hydrolyzes triacylglycerols into fatty acids and monoglycerides, which are then absorbed.
How does gut microbiota affect intestinal lipid catabolism?
Gut microbial fatty acid isomerization can modulate intraepithelial T cells and lipid metabolism.
Conclusion
The intestinal lipid catabolic process (GO:0044258) is a fundamental biological pathway that enables the breakdown and absorption of dietary fats. Its dysregulation is implicated in hypertriglyceridemia, obesity, and malabsorption disorders. Advances in CRISPR-based models and omics technologies are accelerating the discovery of novel regulators and therapeutic targets. EDITGENE provides end-to-end services to support mechanistic studies and drug development in this field.
References
- 1. Choi YJ et al.. 2025. Dual Mechanistic Anti-Obesity Effects of Red Okra and Diospyros lotus Mixture via Fat Binding and AMPK-Mediated Lipid Metabolism.. J Microbiol Biotechnol 35:e2506030 PMID: 41016817
- 2. Duivenvoorden I et al.. 2006. Dietary sphingolipids lower plasma cholesterol and triacylglycerol and prevent liver steatosis in APOE*3Leiden mice.. Am J Clin Nutr 84(2):312-21 PMID: 16895877
- 3. Marks V. 1972. Glucagon.. Clin Endocrinol Metab 1(3):829-45 PMID: 4589705
- 4. Hassing HC et al.. 2012. Pathophysiology of hypertriglyceridemia.. Biochim Biophys Acta 1821(5):826-32 PMID: 22179026
- 5. Lehner R et al.. 1996. Biosynthesis of triacylglycerols.. Prog Lipid Res 35(2):169-201 PMID: 8944226
- 6. Ji L et al.. 2025. Rapeseed oleosomes facilitate intestinal lymphatic delivery and oral bioavailability of cannabidiol.. Int J Pharm 668:124947 PMID: 39550011
- 7. Song X et al.. 2023. Gut microbial fatty acid isomerization modulates intraepithelial T cells.. Nature 619(7971):837-843 PMID: 37380774
- 8. Spaulding SW et al.. 1975. Thyroid-catecholamine interactions.. Med Clin North Am 59(5):1123-31 PMID: 1099359
